New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

• Dolores Isla ^[1] ; Maria D. Lozano ^[2] ; Luis Paz-Ares ^[3] ; Clara Salas ^[4] ; Javier de Castro ^[5] ; Esther Conde ^[8] ; Enriqueta Felip ^[9] ; Javier Gómez-Román ^[6] ; Pilar Garrido ^[7] ; Ana Belén Enguita ^[3]
  1. [1] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  2. [2] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  3. [3] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  4. [4] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  5. [5] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  6. [6] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  7. [7] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  8. [8] Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital Universitario 12 de Octubre, Madrid, España
  9. [9] Hospital Universitario Vall d’Hebron, Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 5 (May), 2023, págs. 1252-1267
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology and the Spanish Society of Medical Oncology have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.